光动力疗法与中心性浆液性脉络膜视网膜病变
Photodynamic therapy and central serous chorioretinopathy.
作者信息
Siaudvytyte Lina, Diliene Vaida, Miniauskiene Goda, Balciuniene Vilma Jurate
机构信息
Eye Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania.
出版信息
Med Hypothesis Discov Innov Ophthalmol. 2012 Winter;1(4):67-71.
Abstract
Central serous chorioretinopathy is a common acquired maculopathy. Multiple studies showed that photodynamic therapy is useful treatment for acute and chronic central serous chorioretinopathy. The exact mechanism of photodynamic therapy in treating central serous chorioretinopathy is not clear, but it is thought to be caused by short-term choriocapillaris hypoperfusion and long-term choroidal vascular remodeling, leading to a reduction in choroidal congestion, vascular hyperpermeability and extravascular leakage. Furthermore, photodynamic therapy seems to be an effective means of improving or stabilizing visual acuity in patients with central serous chorioretinopathy.
摘要
中心性浆液性脉络膜视网膜病变是一种常见的后天性黄斑病变。多项研究表明，光动力疗法是治疗急性和慢性中心性浆液性脉络膜视网膜病变的有效方法。光动力疗法治疗中心性浆液性脉络膜视网膜病变的确切机制尚不清楚，但一般认为是由短期脉络膜毛细血管灌注不足和长期脉络膜血管重塑引起的，导致脉络膜充血、血管高通透性和血管外渗漏减少。此外，光动力疗法似乎是改善或稳定中心性浆液性脉络膜视网膜病变患者视力的有效手段。
相似文献
1
Photodynamic therapy and central serous chorioretinopathy.
Med Hypothesis Discov Innov Ophthalmol. 2012 Winter;1(4):67-71.
2
One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
Retina. 2011 Oct;31(9):1921-7. doi: 10.1097/IAE.0b013e31822bf6b1.
3
Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy.
PLoS One. 2020 Jan 13;15(1):e0227718. doi: 10.1371/journal.pone.0227718. eCollection 2020.
4
Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Retina. 2013 Feb;33(2):316-23. doi: 10.1097/IAE.0b013e318280769c.
5
Atypical Presentation of Chorioretinal Folds-Related Maculopathy.
Optom Vis Sci. 2016 Oct;93(10):1304-14. doi: 10.1097/OPX.0000000000000953.
6
Short-Term Choriocapillaris Changes in Patients with Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy.
Int J Mol Sci. 2017 Nov 20;18(11):2468. doi: 10.3390/ijms18112468.
7
Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy.
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1365-1372. doi: 10.1007/s00417-019-04318-x. Epub 2019 Apr 29.
8
INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Retina. 2019 Jul;39(7):1361-1369. doi: 10.1097/IAE.0000000000002150.
9
[Chronic central serous chorioretinopathy and photodynamic therapy: a case report].
J Fr Ophtalmol. 2008 Dec;31(10):e21. doi: 10.1016/s0181-5512(08)74750-8.
10
Photodynamic therapy in the treatment of choroidal neovascularization complicating central serous chorioretinopathy.
J Chin Med Assoc. 2009 Sep;72(9):501-5. doi: 10.1016/S1726-4901(09)70417-4.
引用本文的文献
1
Imaging in Pachychoroid Disease.
Turk J Ophthalmol. 2025 Feb 27;55(1):36-48. doi: 10.4274/tjo.galenos.2024.40388. Epub 2025 Feb 5.
2
Real-world practice patterns of eplerenone use for central serous chorioretinopathy.
Int J Retina Vitreous. 2023 Oct 2;9(1):61. doi: 10.1186/s40942-023-00500-w.
3
Comparison of the fluorescein angiography-guided and indocyanine green angiography-guided photodynamic therapy in the treatment of non-resolving central serous chorioretinopathy.
Sci Rep. 2023 Jan 30;13(1):1682. doi: 10.1038/s41598-023-28890-9.
4
Comparison of two protocols of subthreshold micropulse yellow laser treatment for non-resolving central serous chorioretinopathy.
Indian J Ophthalmol. 2022 Sep;70(9):3341-3345. doi: 10.4103/ijo.IJO_228_22.
5
Non-Oncologic Applications of Nanomedicine-Based Phototherapy.
Biomedicines. 2021 Jan 25;9(2):113. doi: 10.3390/biomedicines9020113.
6
Association between CFH single nucleotide polymorphisms and response to photodynamic therapy in patients with central serous chorioretinopathy.
Int Ophthalmol. 2020 Apr;40(4):951-956. doi: 10.1007/s10792-019-01261-y. Epub 2020 Jan 10.
7
Central Serous Chorioretinopathy: A Complication Associated with Behçet’s Disease Treatment.
Turk J Ophthalmol. 2019 Feb 28;49(1):40-43. doi: 10.4274/tjo.galenos.2018.83479.
8
Retinal and choroidal changes in steroid-associated central serous chorioretinopathy.
Int J Retina Vitreous. 2018 Apr 2;4:11. doi: 10.1186/s40942-018-0115-1. eCollection 2018.
9
Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy.
Graefes Arch Clin Exp Ophthalmol. 2017 Feb;255(2):243-254. doi: 10.1007/s00417-016-3441-8. Epub 2016 Aug 6.
10
Steroid-induced central serous chorioretinopathy in a patient with non-arteritic anterior ischemic optic neuropathy.
Saudi J Ophthalmol. 2015 Jul-Sep;29(3):232-4. doi: 10.1016/j.sjopt.2015.01.002. Epub 2015 Jan 21.
本文引用的文献
1
Very minimal fluence photodynamic therapy for chronic central serous chorioretinopathy.
Can J Ophthalmol. 2012 Feb;47(1):42-4. doi: 10.1016/j.jcjo.2011.12.020.
2
One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
Retina. 2011 Oct;31(9):1921-7. doi: 10.1097/IAE.0b013e31822bf6b1.
3
Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Retina. 2011 Jan;31(1):119-26. doi: 10.1097/IAE.0b013e3181e378f2.
4
Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.
Retina. 2010 Nov-Dec;30(10):1698-703. doi: 10.1097/IAE.0b013e3181da4354.
5
Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
Ophthalmology. 2010 Sep;117(9):1792-9. doi: 10.1016/j.ophtha.2010.01.023. Epub 2010 May 15.
6
Central serous chorioretinopathy: a personal perspective.
Am J Ophthalmol. 2010 Mar;149(3):361-363. doi: 10.1016/j.ajo.2009.11.017.
7
Photodynamic therapy for chronic central serous chorioretinopathy.
Acta Ophthalmol. 2010 May;88(3):371-6. doi: 10.1111/j.1755-3768.2008.01408.x. Epub 2009 Nov 27.
8
Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy.
Retina. 2009 Nov-Dec;29(10):1469-73. doi: 10.1097/IAE.0b013e3181be0a83.
9
Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
Am J Ophthalmol. 2010 Feb;149(2):307-315.e2. doi: 10.1016/j.ajo.2009.08.026. Epub 2009 Nov 6.
10
Prognostic factors related to photodynamic therapy for central serous chorioretinopathy.
Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1315-23. doi: 10.1007/s00417-009-1104-8. Epub 2009 May 7.
Zotero 插件